KW-2449

DRUG2 trials

Sponsors

Kyowa Kirin, Inc., Kyowa Kirin Co., Ltd.

Conditions

Acute Lymphoblastic LeukemiaAcute Myelogenous LeukemiaAcute Myelogenous Leukemia (AML)Chronic Myelogenous LeukemiaMyelodysplastic Syndromes

Phase 1

An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia

TerminatedNCT00346632

Kyowa Kirin, Inc.Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia +1

Start: 2006-06-30End: 2008-04-30Updated: 2024-05-17

Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)

TerminatedNCT00779480

Kyowa Kirin Co., Ltd.Acute Myelogenous Leukemia (AML)

Start: 2009-01-31End: 2010-12-31Updated: 2024-04-25